Результаты поиска

[Current Approaches in the Diagnosis and Management of Congenital Cytomegalovirus Infections and the Situation in Turkey].

Human cytomegalovirus (CMV) infections are common in all populations and CMV seroprevalence in women of childbearing age is in the range of … the virus. Passive immunization of the pregnant and the treatment of the symptomatic newborns with valganciclovir have yielded positive results. In this review article, maternal, fetal and newborn based current approaches used in the diagnosis and follow-up of congenital CMV infections have been discussed.

Antiviral agents for treatment of herpes simplex virus infection in neonates.

BACKGROUND: Herpes simplex virus (HSV) is a rare but serious neonatal pathogen. Prior to the availability of antiviral drugs the mortality a … to perform. The efficacy of newer antiviral agents with better bioavailability (e.g. valaciclovir, valganciclovir) for the treatment of neonatal disease needs to be evaluated in randomised trials. The efficacy of oral formulations need to be evaluated as they may be useful for infants with skin, eye or mouth HSV disease or in the treatment of infants with recur …

Universal neonatal cytomegalovirus screening using saliva - report of clinical experience.

OBJECTIVES: To analyze the results of a neonatal universal screen for congenital cytomegalovirus (CMV) using saliva real-time polymerase chain reaction (rt-PCR). STUDY DESIGN: During one year (15/5/2011-15/5/2012), saliva was collected from 9845 infants (97% of 10,137 newborns). Viral DNA was extracted by Magna-Pure LC (Roche) and was tested for the presence of CMV IE and gB genes. Urine culture was collected from positive infants for confirmation. For all infants with congenital CMV maternal data were collected and head ultrasound, blood count, liver enzymes, retinal examination and auditory

Cytomegalovirus (CMV) seroprevalence among women at childbearing age, maternal and congenital CMV infection: policy implications of a descriptive, retrospective, community-based study.

BACKGROUND: Maternal CMV infection during pregnancy, either primary or non-primary, may be associated with fetal infection and long-term seq … ng the first 3 weeks of life, neonatal diagnosis of cCMV in the medical records, or prescription of valganciclovir during the neonatal period. RESULTS: The study population Included 45,634 women with 84,110 associated gestational events. Initial CMV serostatus was positive in 89% women, with variation across different ethno-socioeconomic subgroups. Based on con …

[pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation].

INTRODUCTION: Cytomegalovirus (CMV) infection is the most common infectious complication after organ transplantation. Serology is useful onl … ylaxis because it is more expensive and can cause resistance to ganciclovir. A promising novel drug valganciclovir will allow for good prophylaxis owing to its better absorption from the gut. Based on our three-year experience, optimal cut-off for antigenemia has been set at 20 positive cells per 200,000 leukocytes. The existence of symptoms or changes in the le …

Treatment outcome and risk factors for visual loss in Cytomegalovirus endotheliitis.

BACKGROUND: To determine treatment outcome and risk factors for visual loss in Cytomegalovirus (CMV) endotheliitis. METHODS: Retrospective case-note review of all CMV positive endotheliitis patients seen at the Singapore National Eye Center, for demographics, visual acuity (VA), extent of corneal edema, anterior chamber (AC) activity, ocular history, glaucomatous optic neuropathy (GON), and ganciclovir therapy. Outcome measures were VA, corneal edema, and AC activity. RESULTS: Median age at diagnosis of the 19 patients (21 eyes) was 57 years. Median duration of follow up was 37 months. Sixte

False Negative Toxoplasma Serology in an Immunocompromised Patient with PCR Positive Ocular Toxoplasmosis.

PURPOSE: The authors report a case of a 60-year-old Caucasian male with a background of treated Chronic Lymphocytic Leukaemia (CLL) with secondary hypogammaglobulinaemia present with toxoplasma chorioretinitis and negative serum toxoplasma serology on presentation and on subsequent reactivation. METHODS: Retrospective case notes review with fundal photographs. RESULTS: In this case, on initial presentation and on recurrence, the patient's serum anti-Toxoplasma IgG remained negative. The diagnosis was made on quantitative PCR of vitreous initially and aqueous humor on reactivation. CONCLUSIO

Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.

BACKGROUND.: We have shown that high-dose intravenous immune globulin (IVIG; 2 g/kg x2 doses)+rituximab (1 g x2 doses) was effective in lowering anti-human leukocyte antigen (HLA) antibodies and improving rates of transplantation. The aim of this report was to evaluate the efficacy of IVIG+rituximab on reduction of anti-HLA antibodies to a level that was permissive for living donor (LD) or deceased donor (DD) transplantation without incurring the risk of antibody-mediated rejection and immediate graft loss. METHODS.: From July 2006 to February 2009, 76 HLA-sensitized (HS) patients who met stri

Case Report: Kidney Transplantation in a Patient With Acquired Agammaglobulinemia and SLE. Issues and Challenges.

Lupus nephritis in the context of Systemic Lupus Erythematosus (SLE) is characterized by an unpredicted course with remissions and flare-ups. Among others, it remains a significant cause of end-stage kidney disease (ESKD) in relatively young patients. Therapeutic regimens with newer immunosuppressive agents have been introduced in order to control SLE clinical manifestations more efficiently and limit organ damage induced by immune complex formation and sustained inflammation. Treatment is usually long-term, and the cumulative impact of immunosuppression is expressed through the increased freq

Совпадение в полном тексте источника
… Valganciclovir was associated with more episodes of delayed CMV infections especially in seronegative recipients, while hematological toxicity was more frequent in the valganciclovir group ( 19 ). Conclusions regarding the optimal dose of valganciclovir could not be reached ( 19 ). … Close monitoring of CMV replication is to be considered during the direct period post valganciclovir prophylaxis discontinuation in high-risk patients as both myelotoxicity minimization by avoiding prolonged exposure to valganciclovir and proper treatment are feasible ( 18 , 21 ). …

Ablation of proliferating neural stem cells during early life is sufficient to reduce adult hippocampal neurogenesis.

Environmental exposures during early life, but not during adolescence or adulthood, lead to persistent reductions in neurogenesis in the adult hippocampal dentate gyrus (DG). The mechanisms by which early life exposures lead to long-term deficits in neurogenesis remain unclear. Here, we investigated whether targeted ablation of dividing neural stem cells during early life is sufficient to produce long-term decreases in DG neurogenesis. Having previously found that the stem cell lineage is resistant to long-term effects of transient ablation of dividing stem cells during adolescence or adulthoo

Clinical and healthcare burden of disease associated with cytomegalovirus in allogeneic hematopoietic stem cell transplantation - A retrospective single-center study.

BACKGROUND: CMV infection is a common complication in allogeneic hematopoietic stem cell transplantation (HSCT). We investigated the association of clinically significant CMV (CS-CMV) infection with clinical outcomes and healthcare resource utilization in allogeneic HSCT patients in Finland. METHODS: This retrospective study included adult patients who received their first allogeneic HSCT between January 1, 2013, and December 31, 2018, at the Turku University Hospital. Data were collected from the hospital data lake. Clinical and healthcare outcomes were investigated at one year and mortality

Совпадение в полном тексте источника
… In patients with CS‐CMV infection, 73.0% and 62.2% received valganciclovir and foscarnet, respectively. Ganciclovir (36.5%) was less often used. … When clinical improvement is observed, PET is continued after hospital discharge either with intravenously administered ganciclovir or foscarnet in the outpatient clinic, or with per os valganciclovir, and this is seen as a relatively high proportion of patients receiving valganciclovir. …

[Heart transplantation and the subsequent treatment of AL amyloidosis].

UNLABELLED: Severe damage to the heart caused by AL amyloid deposits is a contraindication of high-dose chemotherapy with autologous haemato … t was reduced and a corticosteroid dose was compensatory increased. The prophylactic antiviral drug valganciclovir was discontinued during the haematopoietic stem cell harvest. High-dose chemotherapy (melphalan 100 mg/m2) with autologous haematopoietic stem cell transplantation followed. In the interval from administering melphalan until the rise in neutrophil c …

Critically Ill Immunosuppressed Host

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… 900 mg PO QD For peripheral lesions Valganciclovir 900 mg PO BID for 14-21 days, then 900 mg PO QD Chronic maintenance therapy (Secondary prophylaxis) First choice ▪ Valganciclovir 900 mg PO QD ▪ Foscarnet 90-120 mg/kg body weight IV QD CMV esophagitis or colitis ▪ Ganciclovir IV or Foscarnet IV for … 900 mg PO QD For peripheral lesions Valganciclovir 900 mg PO BID for 14-21 days, then 900 mg PO QD Chronic maintenance therapy (Secondary prophylaxis) First choice ▪ Valganciclovir 900 mg PO QD ▪ Foscarnet 90-120 mg/kg body weight IV QD CMV esophagitis or colitis ▪ Ganciclovir IV or Foscarnet IV for …

Advances in CMV Management: A Single Center Real-Life Experience.

CMV infection is a major challenge in allogeneic stem cell transplantation (allo-SCT). The changing landscape in CMV management includes the introduction of letermovir in prophylaxis of high-risk patients and the source of CMV DNA monitoring (plasma-PL vs. whole blood-WB), for pre-emptive therapy (PET) initiation. We report here how our real-life experience in CMV management evolved, following letermovir registration. We focus on: (i) the effects of systematic use of letermovir for CMV prophylaxis in high-risk patients, (ii) the results of a longitudinal comparison of CMV DNAemia monitoring in

Совпадение в полном тексте источника
… Before the availability of letermovir, the management of CMV infection was based on the monitoring of CMV DNAemia by RT-qPCR and on the prompt use of pre-emptive therapy (PET), either with foscarnet, ganciclovir, or valganciclovir. … PET consisted of foscarnet, ganciclovir, or valganciclovir. Foscarnet was chosen in cases of peripheral blood cytopenia, ganciclovir in cases of renal impairment, and valganciclovir in cases of management of CMV once the patient has been discharged. …

Medical Management of the Kidney Transplant Recipient : Infections and Malignant Neoplasms

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… DHPG, 9-(1,3-dihydroxy-2-propoxymethyl) guanine. 3 Although low-dose valganciclovir, 450 mg daily, has been shown to be effective, the Canadian Society of Transplantation Consensus Workshop on CMV management recommends dosing valganciclovir at 900 mg daily for CMV+ recipients of a CMV+ organ (kidney, … DHPG, 9-(1,3-dihydroxy-2-propoxymethyl) guanine. 3 Although low-dose valganciclovir, 450 mg daily, has been shown to be effective, the Canadian Society of Transplantation Consensus Workshop on CMV management recommends dosing valganciclovir at 900 mg daily for CMV+ recipients of a CMV+ organ (kidney, …

Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.

Infectious complications after allogeneic haematopoietic stem cell transplantation (allo-HCT) remain a clinical challenge. This is a guideline provided by the AGIHO (Infectious Diseases Working Group) of the DGHO (German Society for Hematology and Medical Oncology). A core group of experts prepared a preliminary guideline, which was discussed, reviewed, and approved by the entire working group. The guideline provides clinical recommendations for the preventive management including prophylactic treatment of viral, bacterial, parasitic, and fungal diseases. The guideline focuses on antimicrobial

Совпадение в полном тексте источника
… Valganciclovir is so far not officially approved in allo-HCT patients but has been applied in randomized trials [ 176 , 177 ]. … Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008;111(4):1816–1819. doi: 10.1182/blood-2007-03-080010. 177. Boeckh M, et al. …

Cytomegalovirus reactivation in patients with multiple myeloma receiving bispecific antibodies.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… All patients with cs-CMVi received antiviral treatment: valganciclovir (50%) or foscarnet (50%), with one switching to oral therapy. One foscarnet-treated patient developed nephrotoxicity. Median treatment duration was 21 days (IQR, 12-45). … All survivors received secondary prophylaxis with valganciclovir for a median of 49 days (IQR, 34-63). Univariate analysis suggested association between CMVr and persistent lymphopenia (91% vs 62%; P = .10) and prior CMVr (27% vs 3%; P = .04). …

Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study.

INTRODUCTION: Allogeneic stem cell transplantation is used to cure hematologic malignancies or deficiencies of the hematopoietic system. It is associated with severe immunodeficiency of the host early after transplant and therefore early reactivation of latent herpesviruses such as CMV and EBV within the first 100 days are frequent. Small studies and case series indicated that application of herpes virus specific T cells can control and prevent disease in this patient population. METHODS: We report the results of a randomized controlled multi centre phase I/IIa study (MULTIVIR-01) using a new

Совпадение в полном тексте источника
… Secondary endpoints of the study included the incidence of CMV and EBV reactivation, the use of antiviral drugs such as ganciclovir, valganciclovir, foscavir or cidofovir, and the use of rituximab for the treatment of EBV. … | 0.940 Valganciclovir Treatment Days Mean | 22.0 | 37.1 | 0.212 Valganciclovir Cumulative Dose/Patient mg | 32721±18680 | 26550±20238 | 0.507 EBV Reactivation | 7 | 6 | 0.099 Rituximab Doses/Patient | 2.5±0.7 | 1.67±0.6 | 0.024 Patients treated with Rituximab | 2 | 2 | 0.580 Rituximab Cumulative Dose …

Самые горячие темы трансплантации стволовых клеток: резюме 8th Международный курс трансплантации и клеточной терапии.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Lungman (Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden) concluded that “preemptive therapy in 2023 should still be given primarily with valganciclovir. … Today, we rarely need to give 2nd or 3rd line treatment for CMV; repeated valganciclovir usually works. Occasionally patients have needed foscarnet”. HSCT in acute myeloid leukemia (AML). AML is the most important indication for allogeneic HSCT. E. …

Pneumonia in Transplant Recipients: A Comprehensive Review of Diagnosis and Management.

Transplant recipients have an increased risk of complications, including graft dysfunction and infections, which can be life-threatening if not recognized early. Pneumonia ranks as one of the most frequent complications in both solid organ and hematopoietic stem cell transplants. Clinical symptoms manifest late during infections in immunocompromised patients. An aggressive approach centered on early confirmatory diagnosis and a low threshold for empiric therapy is often the most effective strategy. The isolation of a pathogen in an upper airway sample does not necessarily mean the same organis

Совпадение в полном тексте источника
… CMV The treatment with ganciclovir or valganciclovir has significantly reduced mortality rates. … Although oral valganciclovir possesses good bioavailability, many physicians still prefer intravenous ganciclovir owing to the lack of robust evidence supporting oral valganciclovir. …